|
| |
Price : 5 slide for 600 €
| CL1 Human, kidney cancer |
| |
|
|
|
|
|
|
|
|
|
| |
Age |
Sex |
Diagnosis |
Size(cm) |
Capsule |
Vein |
Other |
N |
M |
| 1 |
52 |
F |
RCC, granular cell types |
12 |
+ |
- |
- |
NX |
M0 |
| 2 |
60 |
F |
RCC, clear cell type |
6 |
+ |
+ |
- |
N0 |
M1 |
| 3 |
42 |
M |
RCC, clear cell type |
9 |
+ |
+ |
- |
NX |
M0 |
| 4 |
59 |
M |
RCC, clear cell type |
7,5 |
+ |
- |
- |
NX |
M0 |
| 5 |
67 |
F |
RCC, clear cell and granular cell type |
8 |
+ |
- |
- |
NX |
M0 |
| 6 |
65 |
M |
RCC, granular and clear cell type |
11 |
+ |
- |
- |
NX |
M0 |
| 7 |
59 |
M |
RCC, clear cell and granular cell type |
7 |
+ |
+ |
- |
NX |
M0 |
| 8 |
56 |
M |
RCC, clear and pseudosarcomatous type |
7 |
+ |
- |
- |
NX |
M1* |
| 9 |
42 |
F |
RCC, clear cell type |
10 |
- |
+ |
- |
NX |
M0 |
| 10 |
50 |
M |
RCC, clear cell type |
3,5 |
- |
- |
- |
N0 |
M0 |
| 11 |
52 |
M |
RCC, clear cell type |
4 |
- |
- |
- |
N0 |
M0 |
| 12 |
68 |
F |
RCC, clear cell type |
6 |
+ |
+ |
- |
N0 |
M0 |
| 13 |
60 |
F |
RCC, clear cell type |
5 |
- |
+ |
- |
N0 |
M0 |
| 14 |
69 |
F |
RCC, clear cell type |
7,5 |
+ |
- |
- |
NX |
M |
| 15 |
54 |
M |
RCC, clear cell type |
7 |
+ |
- |
- |
NX |
M0 |
| 16 |
43 |
F |
RCC, clear cell type |
4 |
+ |
- |
- |
N0 |
M0 |
| 17 |
53 |
M |
RCC, clear cell type |
5,5 |
- |
- |
+* |
NX |
M1** |
| 18 |
. |
M |
RCC, clear cell type |
3,5 |
- |
+ |
- |
N0 |
M0 |
| 19 |
. |
. |
RCC, collecting duct type |
4 |
+ |
- |
- |
NX |
M0 |
| 20 |
40 |
M |
RCC, clear cell type |
2,2 |
- |
- |
- |
NX |
M0 |
| 21 |
52 |
M |
RCC, clear cell type |
6 |
+ |
- |
- |
NX |
M0 |
| 22 |
63 |
F |
RCC, clear cell and granular cell type |
7,5 |
+ |
- |
- |
NX |
M0 |
| 23 |
64 |
M |
RCC, clear cell type |
5,4 |
+ |
- |
- |
NX |
M0 |
| 24 |
37 |
M |
RCC, collecting duct type |
10,5 |
- |
- |
- |
N0 |
M0 |
| 25 |
65 |
M |
RCC, papillary type |
5 |
- |
- |
- |
NX |
M0 |
| 26 |
74 |
M |
RCC, clear type |
17 |
- |
+ |
- |
N0 |
M0 |
| 27 |
67 |
M |
RCC, clear cell type |
9 |
+ |
+ |
+* |
NX |
M0 |
| 28 |
50 |
M |
RCC |
9 |
- |
- |
- |
N0 |
M0 |
| 29 |
74 |
M |
RCC, clear cell type |
17 |
- |
+ |
- |
N0 |
M0 |
| 30 |
62 |
M |
RCC, clear granular cell |
7 |
+ |
+ |
- |
NX |
M0 |
| 31 |
64 |
M |
RCC, papillary type |
4 |
- |
- |
- |
NX |
M0 |
| 32 |
45 |
M |
RCC, clear cell type |
6,5 |
- |
- |
- |
N0 |
M0 |
| 33 |
62 |
M |
RCC |
10 |
+ |
- |
- |
N1 |
M0 |
| 34 |
53 |
M |
RCC, clear cell type |
4,5 |
+ |
- |
- |
NX |
M0 |
| 35 |
64 |
M |
RCC, clear cell type |
6 |
- |
- |
- |
NX |
M0 |
| 36 |
72 |
M |
RCC, clear cell type |
1,5 |
- |
- |
- |
NX |
M0 |
| 37 |
62 |
F |
RCC, clear cell type |
11 |
- |
- |
+* |
NX |
M0 |
| 38 |
56 |
M |
RCC, clear cell type |
4 |
+ |
+ |
- |
NX |
M0 |
| 39 |
58 |
M |
RCC |
8,5 |
- |
- |
- |
NX |
M0 |
| 40 |
57 |
M |
RCC, clear cell and granular cell type |
10 |
+ |
- |
- |
N0 |
M0 |
| 41 |
64 |
F |
Transitional cell carcinoma, pelvis |
. |
. |
. |
. |
. |
. |
| 42 |
43 |
F |
RCC, clear cell type |
6 |
- |
- |
- |
NX |
M0 |
| 43 |
52 |
F |
RCC, granular cell type |
7 |
- |
- |
- |
NX |
M0 |
| 44 |
64 |
M |
RCC, granular cell type |
10 |
- |
+ |
+* |
NX |
M0 |
| 45 |
57 |
M |
RCC, clear cell type |
4,5 |
+ |
- |
- |
NX |
M0 |
| 46 |
59 |
M |
RCC, clear cell type and granular cell type |
8 |
+ |
- |
- |
NX |
M0 |
| 47 |
47 |
M |
RCC, clear cell type |
4 |
+ |
- |
- |
NX |
M0 |
| 48 |
77 |
M |
RCC, clear cell type |
2,5 |
+ |
- |
- |
NX |
M0 |
| 49 |
47 |
F |
RCC, clear and granular cell type |
8 |
+ |
- |
- |
NX |
M0 |
| 50 |
55 |
F |
RCC, clear cell type |
3 |
+ |
- |
- |
NX |
M0 |
| 51 |
Normal of No. 4 |
| 52 |
Normal of No. 16 |
| 53 |
Normal of No. 20 |
| 54 |
Normal of No. 21 |
| 55 |
Normal of No. 30 |
| 56 |
Normal of No. 36 |
| 57 |
Normal of No. 42 |
| 58 |
Normal of No. 48 |
| 59 |
Normal of No. 50 |
| 60 |
Carbon particles |
| |
|
|
|
|
|
|
|
|
|
| #2 * lung metastasis |
|
|
|
|
|
|
|
| #8 *: metastasis to contralateral kidney |
|
|
|
|
|
|
| #17 *: perinephric fat involvement, **: bone metastasis |
|
|
|
|
|
|
| #27 *: adrenal gland involvement, Gerota's fascia involvement |
|
|
|
|
|
|
| #37 *: perinephric fat involvement |
|
|
|
|
|
|
| #44 *: perinephric fat involvement |
|
|
|
|
|
|
General Information of the Tissue Array Slide :
Applications
- Immunohistochemistry
- In situ hybridization, RNA or DNA
- Fluorescent in situ hybridization (FISH)
- In situ PCR, RNA or DNA
- TUNEL for apoptosis (Recommended procedures in
www.tissue-array.com -> protocol)
Storage and stability
- Individual slide is paraffin-coated and put in an air-tight pack
with inert gas.
- Tissue array slides are shipped in room temperature.
- If the slides are stored in 4 degree, they are good up to one
year.
How processed
- Tissues were initially fixed with formalin except for some of the
animal tissues.
- Then, dehydrated with gradient ethanol; typically 1 hour each
progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
- Cleared by xylene, three changes for 1 hour each.
- Infiltrated with 60°C paraffin, three changes for 1 hour each
- Microtoming in 4 µm thickness and put on silane coating slide from
Muto Pure Chemicals (Japan)
Before use
- Dry slides for 1 hour in a oven at 60 degree.
- Dewax slides in xylene for 4 minutes x 5 times
- Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2
times each.
- Immerse slides in tap water for 5 minutes
Slide orientation
- In most of the slides with 59 or 60 cores, the orientation is as
below unless indicated otherwise. #60 location is usually filled with carbon
for orientation.
| 1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
| 11 |
12 |
13 |
14 |
15 |
16 |
17 |
18 |
19 |
20 |
| 21 |
22 |
23 |
24 |
25 |
26 |
27 |
28 |
29 |
30 |
| 31 |
32 |
33 |
34 |
35 |
36 |
37 |
38 |
39 |
40 |
| 41 |
42 |
43 |
44 |
45 |
46 |
47 |
48 |
49 |
50 |
| 51 |
52 |
53 |
54 |
55 |
56 |
57 |
58 |
59 |
60 |
|